Apellis Pharmaceuticals Files 2024 10-K

Ticker: APLS · Form: 10-K · Filed: Feb 28, 2025 · CIK: 1492422

Apellis Pharmaceuticals, INC. 10-K Filing Summary
FieldDetail
CompanyApellis Pharmaceuticals, INC. (APLS)
Form Type10-K
Filed DateFeb 28, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

Related Tickers: APLS

TL;DR

APLS filed its 2024 10-K. Full financials and biz details inside.

AI Summary

Apellis Pharmaceuticals, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector. Key financial data and business operations for the period are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Apellis Pharmaceuticals' financial performance, strategic initiatives, and risk factors for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Apellis faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Apellis Pharmaceuticals, Inc.?

Apellis Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.

When did Apellis Pharmaceuticals, Inc. file its 10-K report?

The 10-K report was filed on February 28, 2025.

What fiscal year does this 10-K filing cover?

This 10-K filing covers the fiscal year ending December 31, 2024.

Where is Apellis Pharmaceuticals, Inc. headquartered?

The company's business address is located in Waltham, MA.

What is the SEC file number for Apellis Pharmaceuticals, Inc.'s 10-K?

The SEC file number is 001-38276.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing